Nadig C, Binswanger U, von Felten A
Department of Nephrology, University Hospital, Zurich, Switzerland.
Perit Dial Int. 1997 Sep-Oct;17(5):493-6.
Heparin therapy in continuous ambulatory peritoneal dialysis (CAPD) peritonitis seems well established; it is costly due to the necessity of hospitalization. There are no clinical studies that show a benefit of such a treatment. The aim of this study was to investigate whether heparin therapy in CAPD peritonitis is necessary.
194 samples of peritoneal dialysates were collected from 17 patients over a period of 24 months. Samples were subdivided into three groups: those without peritonitis (< 100 leukocytes/microL), those with mild peritonitis (100-499 leukocytes/microL), and those with severe peritonitis (> or = 500 leukocytes/microL).
The number of leukocytes per microL dialysate and total protein concentrations were determined. Furthermore, dialysate concentrations of thrombin-antithrombin III- (TAT-) complexes (indicator of thrombin formation), D-dimers (indicator of fibrinolysis), and plasminogen activator inhibitor 1 (PAI-1) were measured.
The dialysate protein concentration progressively increased from no peritonitis to mild and severe inflammation. In parallel, dialysate TAT-complex and D-dimer concentrations increased. Thrombin-antithrombin III-complex and D-dimer concentrations correlated strongly in 179 cases (r = 0.76; 62 samples showing peritonitis, 117 samples with no evidence of peritonitis). In the remaining 15 samples of 3 patients, high PAI-1 levels (> 40 ng/mL) and low D-dimer concentrations were found. Eleven of the 15 samples showed evidence of peritonitis. In these 11 samples with evidence of peritonitis, high levels of TAT-complexes were detected, while D-dimer concentrations were found to be very low, pointing to a blocked fibrinolysis. The PAI-1 levels were not related to leukocyte counts or protein concentrations in the dialysates.
Based on our findings, the routine intraperitoneal administration of heparin in CAPD peritonitis is not necessary. In rare cases an imbalance between coagulation and fibrinolysis due to high PAI-1 levels exists (15 of 194 dialysate samples, 11 of the 15 samples showing peritonitis). These cases--which do require heparinization--can be identified by demonstrating low D-dimer levels in CAPD dialysate at times of peritonitis.
持续非卧床腹膜透析(CAPD)相关性腹膜炎的肝素治疗似乎已得到广泛认可;但由于需要住院治疗,费用较高。尚无临床研究表明这种治疗有何益处。本研究的目的是调查CAPD相关性腹膜炎的肝素治疗是否必要。
在24个月的时间里,从17名患者身上收集了194份腹膜透析液样本。样本分为三组:无腹膜炎组(白细胞<100/微升)、轻度腹膜炎组(白细胞100 - 499/微升)和重度腹膜炎组(白细胞≥500/微升)。
测定每微升透析液中的白细胞数量和总蛋白浓度。此外,还测量了透析液中凝血酶 - 抗凝血酶III复合物(TAT - 复合物,凝血酶形成的指标)、D - 二聚体(纤维蛋白溶解的指标)和纤溶酶原激活物抑制剂1(PAI - 1)的浓度。
透析液蛋白浓度从无腹膜炎逐渐升高至轻度和重度炎症。与此同时,透析液中TAT - 复合物和D - 二聚体浓度升高。在179例病例中,凝血酶 - 抗凝血酶III复合物和D - 二聚体浓度呈强相关(r = 0.76;62份样本显示有腹膜炎,117份样本无腹膜炎迹象)。在其余3例患者的15份样本中,发现PAI - 1水平较高(>40 ng/mL)且D - 二聚体浓度较低。15份样本中有11份显示有腹膜炎迹象。在这11份有腹膜炎迹象的样本中,检测到高水平的TAT - 复合物,而D - 二聚体浓度非常低,表明纤维蛋白溶解受阻。PAI - 1水平与透析液中的白细胞计数或蛋白浓度无关。
根据我们的研究结果,CAPD相关性腹膜炎常规腹腔内给予肝素并非必要。在极少数情况下,由于PAI - 1水平较高,会出现凝血与纤维蛋白溶解失衡的情况(194份透析液样本中有15份,15份样本中有11份显示有腹膜炎)。这些确实需要肝素化的病例,可以通过在腹膜炎发作时CAPD透析液中D - 二聚体水平较低来识别。